Mark October 17th on the calendar. This is the day that Prime Minister Justin Trudeau of Canada will sign a piece of legislation into law that fully legalizes recreational cannabis.
LONDON, /PRNewswire/ -- Mark October 17th on the calendar. This is the day that Prime Minister Justin Trudeau of Canada will sign a piece of legislation into law that fully legalizes recreational cannabis. It will unlock a market that could be worth $22.6 billion per year. But, the pot stock story is hardly over. Mentioned in today's commentary includes: Compass Diversified Holdings (NYSE:CODI), Teva Pharmaceuticals (NYSE:TEVA), Innovative Industrial Properties (NYSE:IIPR), Canopy Growth (OTC:TWMJF), Beleave Inc. (OTC:BLEVF). In fact - it appears markets are now entering Phase 2 of the global marijuana revolution. And one company is making big waves. On Monday, July 16th Scythian Biosciences (SCYB, SCCYF) announced the sale of their Latin American and Jamaican assets to Aphria for what was then $193,000,000. As of September 27th that deal has now officially closed. The transaction includes 15,780,000 shares of Aphria stock. On the date of closing the deal, Aphria's share price was $17.78, giving a value of $280,568,400 to their position. Which could become Scythian's "war chest" for Phase 2 of the cannabis global legalization march. The company is now targeting the 1.37 billion potential consumers around the world especially in the United States but also Europe. Scythian Biosciences aims to exploit their massive capital position to become one of the world's first truly global cannabis industry incubators. They've developed and flipped major assets in Colombia, Jamaica and Argentina. And, with plenty of projects in their incubation pipeline - they're just getting started. Now they're targeting Brazil, Europe and the United States. Here are five key reasons investors are keeping Scythian Biosciences (SCYB, SCCYF) on their radar: On The Eve of Canadian Legalization On June 7th, 2018 the Senate of Canada approved the Trudeau government's landmark legislation to end cannabis prohibition in Canada. After months of furious debate, the Prime Minister has announced that Bill C-45 - The Cannabis-Act - will become law on the 17th of October 2018. For the Canadian pot industry, it was a momentous occasion. The World's First Cannabis Incubator Breakthrough Cannabinoid Therapies Scythian Biosciences (SCYB, SCCYF) intends to create a range of cannabis consumer brands, to be distributed through their own digital platforms, retail units and via partners. They are also developing a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. According to the CDC, there were about 2.8 million TBI-related emergency department (ED) visits, hospitalizations, and deaths in the United States in 2013. Scythian believes its unique cannabinoid technology can mitigate brain damage caused by concussions by easing the aftereffects of the brain's contact with the skull. This technology is covered by Scythian's first patent application. Scythian's second patent filing covers methods for treating gastrointestinal inflammation in chronic diseases such as irritable bowel syndrome and Crohn's disease. A World Class Management Team CEO - Rob Reid Mr. Reid is a leading business figure in Europe's legal cannabis industry. He is co-founder of Prohibition Partners, a company that provides market data and intelligence to investors, entrepreneurs and regulators. He is also co-founder of Cannabis Europa, a conference series that will focus on the science and policy required to shape the future of Europe's medical cannabis industry. Chief Medical Officer - Michael Barnes Professor Barnes MD FRCP is a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe. He is the Honorary Professor of Neurological Rehabilitation at the University of Newcastle, and Founder and President of the World Federation of Neurological Rehabilitation. He's also the past President of the British Society of Rehabilitation Medicine and was elected to the membership of the European Academy of Rehabilitation Medicine.
The problem with stocks of this size, of course, is that the upside is unlikely to be near the upside of those new and dynamic smaller players in the space - but the downside is far more appealing for a conservative investor. By. Joao Peixe **IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY** Notice for Forward-Looking Information Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that investor interest in the cannabis sector will continue to grow to October 17, 2018 and beyond; that cannabis use and sales will grow as currently predicted; Scythian's intended acquisition of various foreign companies and expansion into the US market; that the Aphria stock owned by Scythian will retain its current value and that Scythian can realize a profit on its sale; Scythian's plans to incubate projects in various locations throughout the world; that it could be granted licensable patents; that Scythian will get an exclusive cannabis distribution license in Florida; that Scythian will create a range of cannabis consumer brands, to be distributed through their own digital platforms, retail units and via partners, that Scythian can develop a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury; and that it will be able to carry out its business plans. Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Scythian. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets Scythian operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; Scythian not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; Scythian's technology may not achieve the expected results and its accomplishments may be limited; Florida may not grant to Scythian an exclusive cannabis medical license; even if it is granted the Florida license, Scythian may not be able to profitably use it; Scythian may not successfully develop a cannabis consumer brand; and it may not be successful in developing a cannabis based treatment for concussions and brain therapy; even if it develops a successful treatment, it may not be able to protect its intellectual property; its patent applications may be rejected or successfully challenged; Scythian's business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; and regulatory risks relating to Scythian's business, financings and strategic acquisitions. DISCLAIMERS
DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information: FN Media Group LLC SOURCE Safehaven.com |
||
Company Codes: NYSE:CODI, NYSE:TEVA, NYSE:IIPR, OTC-BB:TWMJF, OTC-BB:BLEVF |